Skip to main content


Table 2 Primary and secondary outcomes

From: Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial

Primary outcome Secondary outcomes
HPR (PR ≥ 240 units) Death from cardiovascular cause
  Myocardial infarction
  Stent thrombosis
  Hemorrhagic or non-hemorrhagic stroke
  Target vessel revascularization
  Bleeding event defined by Thrombolysis in Myocardial Infarction (TIMI) criteria and BARC
  1. HPR, high platelet reactivity: more than 240 units determined via VerifyNow (Accumetrics, San Diego, CA, USA); PR, platelet reactivity; BARC, bleeding academic research consortium.